Evidence map›Paper›PMID 42635853›Full record

ArticleJournal of neuro-oncology2026

Molecular features of intratumoral hemorrhage in glioblastoma isocitrate dehydrogenase-wildtype.

Angel Bueno, Antonio Dono, Oscar Alcantar, Christian Amezquita-Contreras, Laura Ocasio, Sigmund Hsu, Mark Amsbaugh, Jay-Jiguang Zhu, Angel I Blanco, Roy F Riascos and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Angel BuenoVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Antonio DonoVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Oscar AlcantarVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Christian Amezquita-ContrerasVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Laura OcasioDepartment of Diagnostic and Interventional Imaging, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Sigmund HsuVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Mark AmsbaughVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Jay-Jiguang ZhuVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Angel I BlancoVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Roy F RiascosDepartment of Diagnostic and Interventional Imaging, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Leomar Y BallesterDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Nitin TandonVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Yoshua EsquenaziVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. Yoshua.EsquenaziLevy@uth.tmc.edu.ORCID http://orcid.org/0000-0002-9757-1453

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma isocitrate dehydrogenase (IDH)-wildtype (GBM) has been reclassified based on molecular and phenotypic features. Intratumoral hemorrhage is a phenotypic subtype with poorly understood molecular and clinical characteristics. We aimed to characterize the molecular profile and outcomes of hemorrhagic glioblastoma (hGBM) compared with non-hGBM.

methodsA retrospective analysis of GBMs with pre-operative and post-operative MRI and comprehensive next-generation sequencing of 205 genes was performed. Patients were classified as hGBM or non-hGBM using the Visually Accessible Rembrandt Images criteria. Univariable and multivariable survival analyses were performed. Genes were compared using the Fisher-exact test and corrected for multiple comparisons with the Benjamini-Hochberg method.

results176 patients were included, of whom 105 had hGBM. Compared to non-hGBMs, hGBMs were more likely Hispanic (20.0% vs. 7.0%, p = 0.018), presented with motor deficits (38.0% vs. 21.1%, p = 0.020), and had larger tumors (147.6 cm

conclusionshGBMs might be associated with lower frequencies of PDGFRA, KIT, KDR, and PIK3R1 alterations and higher frequencies of SETD2 alterations compared to non-hGBMs. No outcome differences were observed by intratumoral hemorrhage status in this cohort.

Indexed as

Biomarkers, TumorBrain NeoplasmsGlioblastomaIsocitrate DehydrogenaseMutationAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorIDH1 protein, humanIsocitrate DehydrogenaseGBMHemorrhagicKDRKITPDGFRAPIK3R1

Identifiers

PMID42635853
PMCPMC13503418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.